Martina Pagliuca
Ricercatore in tenure track
- GSD 06/MEDS-09; SSD MEDS-09/A
- m.pagliuca@ssmeridionale.it
- Via Mezzocannone, n.4-80134 (NA)
- Area Interdisciplinare Scientifico-Tecnologica
Bio
Martina Pagliuca è un Medico Oncologo. Attualmente è Ricercatrice (RTT) presso la Scuola Superiore Meridionale di Napoli. Dal 2021 al 2024 ha ricoperto il ruolo di Research Fellow presso il prestigioso Gustave Roussy Cancer Campus di Villejuif, Parigi (Francia), dove è tuttora parte del Breast Cancer Survivorship Research Group e dell’unità di Molecular Predictors and New Targets in Oncology. Il suo lavoro si concentra sulla personalizzazione delle strategie di trattamento e ottimizzazione della qualità di vita per i pazienti oncologici e sull’identificazione di biomarcatori molecolari.
Dopo aver conseguito la laurea in Medicina e Chirurgia con lode presso l’Università di Napoli “Federico II”, ha completato la specializzazione in Oncologia Medica. Durante la sua formazione, ha svolto attività cliniche e di ricerca presso istituzioni di eccellenza, tra cui l’Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale” di Napoli, affinando le sue competenze nella gestione multidisciplinare del paziente oncologico e nell’elaborazione di protocolli sperimentali.
Parallelamente alla sua attività clinica e di ricerca, attualmente porta avanti un dottorato di ricerca in cotutela di tesi internazionale tra le scuole: Cancérologie, Biologie, Médecine, Santé dell’Università Paris-Saclay e Clinical and Translational Oncology della Scuola Superiore Meridionale di Napoli. Inoltre, ha conseguito due diplomi universitari in ricerca clinica e traslazionale e in oncologia presso la stessa Università Paris-Saclay, arricchendo la sua formazione con competenze avanzate in metodologia della ricerca e analisi dei dati.
Il suo impegno nella comunità scientifica è testimoniato dalla sua partecipazione attiva come relatrice a congressi nazionali e internazionali, nonché dal suo ruolo di Editor per riviste scientifiche. Ha ricevuto numerosi riconoscimenti per il suo lavoro, tra cui il Conquer Cancer® Merit Award della ASCO Foundation.
Ricerca
Martina Pagliuca ha una solida esperienza in oncologia clinica e traslazionale, con particolare interesse nella ricerca sul carcinoma mammario, qualità di vita e cancer survivorship.
Martina Pagliuca è membro di società scientifiche di rilievo come ASCO, ESMO, AACR e AIOM, e collabora con network internazionali di ricerca in oncologia. Oltre alle sue competenze cliniche e scientifiche, ha una solida preparazione nell’analisi statistica applicata alla ricerca biomedica, con conoscenze avanzate di programmazione in SAS e metodologia GRADE per l’elaborazione di linee guida cliniche.
Con una forte passione per la medicina personalizzata e la ricerca traslazionale, Martina Pagliuca lavora per contribuire all’innovazione in oncologia, con l’obiettivo di migliorare la qualità di vita e le prospettive terapeutiche per i pazienti oncologici.
Pubblicazioni
Articoli su riviste scientifiche
1. Long-term behavioral symptom clusters among survivors of early-stage breast cancer: Development and validation of a predictive model
2025 JNCI: Journal of the National Cancer Institute https://doi.org/10.1093/jnci/djae222
Martina Pagliuca, MD, Julie Havas, MSc, Emilie Thomas, MSc, Youenn Drouet, PhD, Davide Soldato, MD, Maria Alice Franzoi, MD, Joana Ribeiro, MD, Camila K Chiodi, MD, Emma Gillanders, BA, Barbara Pistilli, MD, Gwenn Menvielle, PhD, Florence Joly, MD, Florence Lerebours, MD, Olivier Rigal, MD, Thierry Petit, MD, PhD, Sylvie Giacchetti, MD, Florence Dalenc, MD, PhD, Johanna Wassermann, MD, MSPH, Olivier Arsene, MD, Anne Laure Martin, PhD, Sibille Everhard, PhD, Olivier Tredan, MD, PhD, Sandrine Boyault, MSc, Michelino De Laurentiis, MD, PhD, Alain Viari, PhD, Jean Francois Deleuze, PhD, Aurelie Bertaut, MD, PhD, Fabrice André, MD, PhD, Ines Vaz-Luis, MD, PhD, Antonio Di Meglio, MD, PhD
2. CAR-T cell therapy for breast cancer: Current status and future perspective
2024 Cancer Treatment Reviews
Giuseppe Buono, Monica Capozzi, Roberta Caputo, Vincenzo Di Lauro, Daniela Cianniello, Michela Piezzo, Stefania Cocco, Claudia Martinelli, Annarita Verrazzo, Margherita Tafuro, Claudia Calderaio, Alessandra Calabrese, Francesco Nuzzo, Martina Pagliuca, Michelino De Laurentiis
3. A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later
2024 Annals of Oncology
https://doi.org/10.1016/j.annonc.2024.07.728
A. Di Meglio ∙ J. Havas ∙ M. Pagliuca ∙ M.A. Franzoi ∙ D. Soldato ∙ C.K. Chiodi ∙ E. Gillanders ∙ F. Dubuisson ∙ V. Camara-Clayette ∙ B. Pistilli ∙ J. Ribeiro ∙ F. Joly ∙ P.H. Cottu ∙ O. Tredan ∙ A. Bertaut ∙ P.A. Ganz ∙ J. Bower ∙ A.H. Partridge ∙ A.L. Martin ∙ S. Everhard ∙ S. Boyault ∙ S. Brutin ∙ F. André ∙ S. Michiels ∙ C. Pradon ∙ I. Vaz-Luis
4. Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
2024 British Journal of Cancer
10.1038/s41416-024-02766-9
F. Poumeaud, M. Morisseau, L. Cabel, A. Gonçalves, C. Rivier, O. Trédan, E. Volant, J.-S. Frenel, S. Ladoire, W. Jacot, M. Jamelot, H. Foka Tichoue, A. Patsouris, L. Teixeira, F.-C. Bidard, D. Loirat, M. Brunet, C. Levy, C. Bailleux, B. Cabarrou, A. Deleuze, L. Uwer, E. Deluche, T. Grellety, C. Franchet, F. Fiteni, H. Bischoff, R. Vion, M. Pagliuca, B. Verret, S. Bécourt, T. Reverdy, A. de Nonneville & F. Dalenc
5. Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis
2024 The Breast
Buonaiuto R, Caltavituro A, Tafuro M, Longobardi A, Pavone G, De Santis P, Caputo R, De Angelis C, Del Mastro L, Puglisi F, Giuliano M, Arpino G, Pagliuca M, De Laurentiis M
6. Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium
2024 The Lancet Regional health – Europe
Franzoi MA, Ferreira A, Lemaire A, Rodriguez J, Grosjean J, Ribeiro JM, Polastro L, Grellety T, Artignan X, Le Du K, Pagliuca M, Nouhaud E, Autheman M, André F, Basch E, Metzger O, Ferté C, Di Palma M, Scotté F, Vaz-Luis I
7. Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer
2024 Journal of Clinical Oncology
https://doi.org/10.1200/JCO.23.01959
Soldato S, Michiels S, Havas J, Di Meglio A, Pagliuca M, Franzoi MA, Pistilli B, Iyengar NM, Cottu P, LErebours F, Coutant C, Bertaut A, Tredan O, Vanlemmens L, Jouannaud C, Hrab I, Everhard S, MArtin AL, André F, Vaz-Luis I, Jones LW
8. International Society for Extracellular Vesicles workshop. QuantitatEVs: Multiscale analyses, from bulk to single extracellular vesicle
2024 Journal of Extracellular Biology
http://doi.org/10.1002/jex2.137
Basso M, Gori A, Nardella C, Palviainen M, Holcar M, Sotiropoulos I, Bobis-Wozowicz S, D’Agostino VG, Casarotto E, Ciani Y, Suetsugu S, Gualerzi A, Martin-Jaular L, Boselli D, Kashkanova A, Parisse P, Lippens L, Pagliuca M, Blessing M, Frigerio R, Fourniols T, Meliciano A, Fietta A, Fioretti PV, Soroczyńska K, Picciolini S, Salviano-Silva A, Bergese P, Zocco D, Chiari M, JensterG, Waldron L, Milosavljevic A, Nolan J, Monopoli MP, Witwer KW, Bussolati B, Di Vizio D, Falcon Perez J, Lenassi M, Cretich M, Demichelis F
9. Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
2023 EClinicalMedicine
D’Arienzo A, Verrazzo A, Pagliuca M, Napolitano F, Parola S, Viggiani M, Caputo R, Puglisi F, Giuliano M, Del Mastro L, Arpino G, De Laurentiis M, Montemurro F
10. Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion
2023 Future Oncology
Caputo R, Buono G, Di Lauro V, Cianniello D, Von Arx C, Pensabene M, Pagliuca M, Pacilio C, Di Rella F, Verrazzo A, Martinelli C, Nuzzo F, De Laurentiis M
11. Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case report
2023 Frontiers in Oncology
Caputo R, Pagliuca M, Pensabene M, Parola S, De Laurentiis M
12. Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype
2023 Biomedicines
https://doi.org/10.3390/biomedicines11030874
Aldo Caltavituro, Roberto Buonaiuto, Erica Pietroluongo, Rocco Morra, Fabio Salomone, Pietro De Placido, Martina Pagliuca, Angelo Vaia, Margaret Ottaviano, Marianna Tortora, Sabino De Placido, Giovannella Palmieri, Mario Giuliano
13. New steps on an old path: Novel estrogen receptor inhibitors in breast cancer
2022 Critical Reviews in Oncology/Hematology
https://doi.org/10.1016/j.critrevonc.2022.103861
Pagliuca M, Donato M, Lagodin D’Amato A, Rosanova M, Russo AOM, Scafetta R, De Angelis C, Trivedi MV, André F, Arpino G, Del Mastro L, De Laurentiis M, Puglisi F, Giuliano M
14. Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient’s Phenotype History Doesn’t Lie.
2021 Frontiers in Oncology
https://doi.org/10.3389/fonc.2021.602523
De Angelis C, Nardelli C, Concolino P, Pagliuca M, Setaro M, De Paolis E, De Placido P, Forestieri V, Scaglione GL, Ranieri A, Lombardo B, Pastore L, De Placido S, Capoluongo E.
15. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists
2020 Journal for ImmunoTherapy of Cancer
http://dx.doi.org/10.1136/jitc-2020-001154
Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, Aieta M, Assalone P, Attademo L, Avallone A, Bloise F, Bosso D, Borzillo V, Buono G, Calderoni G, Caputo F, Cartenì G, Cavallero D, Cavo A, Ciardiello F, Conca R, Conteduca V, De Falco S, De Felice M, De Laurentiis M, De Placido P, De Placido S, De Santo I, De Stefano A, Della Corte CM, Di Franco R, Di Lauro V, Fabbrocini A, Federico P, Festino L, Giordano P, Giuliano M, Gridelli C, Grimaldi AM, Lia M, Marretta AL, Massa V, Mennitto A, Merler S, Merz V, Messina C, Messina M, Milano M, Minisini AM, Montesarchio V, Morabito A, Morgillo F, Mucci B, Nappi L, Napolitano F, Paciolla I, Pagliuca M, Palmieri G, Parola S, Pepe S, Petrillo A, Piantedosi F, Piccin L, Picozzi F, Pietroluongo E, Pignata S, Prati V, Riccio V, Rosanova M, Rossi A, Russo A, Salati M, Santabarbara G, Sbrana A, Simeone E, Silvestri A, Spada M, Tarantino P, Taveggia P, Tomei F, Vincenzo T, Trapani D, Trojanello C, Vanella V, Vari S, Ventriglia J, Vitale MG, Vitiello F, Vivaldi C, von Arx C, Zacchi F, Zampiva I, Zivi A, Daniele B, Ascierto PA
16. Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
2020 Cancers
https://doi.org/10.3390/cancers12020408
Buonerba C, Dolce P, Iaccarino S, Scafuri L, Verde A, Costabile F, Pagliuca M, Morra R, Riccio V, Ribera D, De Placido P, Romeo V, Crocetto F, Longo N, Imbimbo C, De Placido S, Di Lorenzo G
17. Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis
2019 Cancers
https://doi.org/10.3390/cancers11091259
Buonerba C, Iaccarino S, Dolce P, Pagliuca M, Izzo M, Scafuri L, Costabile F, Riccio V, Ribera D, Mucci B, Carrano S, Picozzi F, Bosso D, Formisano L, Bianco R, De Placido S, Di Lorenzo G.
18. The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer
2019 Drugs
https://doi.org/10.1007/s40265-019-1060-5
Pagliuca M, Buonerba C, Fizazi K, Di Lorenzo G.
19. Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial
2018 Frontiers in Pharmacology
https://doi.org/10.3389/fphar.2018.00189
Buonerba C, De Placido P, Bruzzese D, Pagliuca M, Ungaro P, Bosso D, Ribera D, Iaccarino S, Scafuri L, Liotti A, Romeo V, Izzo M, Perri F, Casale B, Grimaldi G, Vitrone F, Brunetti A, Terracciano D, Marinelli A, De Placido S, Di Lorenzo G
20. The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer
2017 Journal of Cancer
https://doi.org/10.7150/jca.20040
Buonerba C, Sonpavde G, Vitrone F, Bosso D, Puglia L, Izzo M, Iaccarino S, Scafuri L, Muratore M, Foschini F, Mucci B, Tortora V, Pagliuca M, Ribera D, Riccio V, Morra R, Mosca M, Cesarano N, Di Costanzo I, De Placido S, Di Lorenzo G
21. PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study
2017 Medicine
https://doi.org/10.1097/md.0000000000006817
Bosso D, Pagliuca M, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Cartenì G, Daniele B, Morelli F, Ferro M, Puglia L, Izzo M, Montanaro V, Bellelli T, Vitrone F, De Placido S, Buonerba C, Di Lorenzo G
22. Immunotherapy for penile cancer
2017 Future science OA
https://doi.org/10.4155/fsoa-2017-0031
Buonerba C, Pagliuca M, Vitrone FM, Ascione I, Elefante I, Riccio V, Romano F, De Placido S, Di Lorenzo G
23. The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review
2016 Expert Opinion on Biological Therapy
https://doi.org/10.1080/14712598.2016.1216964
Di Lorenzo G, De Placido S, Pagliuca M, Ferro M, Lucarelli G, Rossetti S, Bosso D, Puglia L, Pignataro P, Ascione I, De Cobelli O, Caraglia M, Aieta M, Terracciano D, Facchini G, Buonerba C, Sonpavde G
24. Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature
2016 Medicine
https://doi.org/10.1097/md.0000000000002754
Di Lorenzo G, Pagliuca M, Perillo T, Benincasa A, Bosso D, De Placido S, Buonerba C
25. Complete Response and Fatigue Improvement With the Combined Use of Cyclophosphamide and Quercetin in a Patient With Metastatic Bladder Cancer: A Case Report
2016 Medicine
https://doi.org/10.1097./md.0000000000002598
Di Lorenzo G, Pagliuca M, Perillo T, Zarrella A, Verde A, De Placido S, Buonerba C
Capitoli in libri
Complications – Lung metastases
2023 Chapter of the Textbook Metastatic Breast Cancer – Treatment and Management, Minerva Medica
First-line therapy with atezolizumab in patient with triple-negative breast cancer without evidence of disease
07/2021 Chapter of the Textbook Breast Cancer and Immunotherapy, Edra
Abstract e Poster
1. Clinical characteristics and survival outcome of patients with early discontinuation of first-line (1L) cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) therapy for HR+/HER2- advanced breast cancer: a nationwide, real-world study
San Antonio Breast Cancer Symposium (SABCS) 2024 Abstract P1-08-12
Martina Pagliuca, Alexandre Lolivier, Benjamin Verret, Barbara Pistilli, Michelino De Laurentiis, Antonio Di Meglio, Stefan Michiels, Fabrice André, Stephanie Foulon
2. Genome-wide association study (GWAS) of aromatase inhibitor musculoskeletal toxicity (AIMT) among early-stage breast cancer (BC) survivors.
San Antonio Breast Cancer Symposium (SABCS) 2024 Abstract PS15-02
Pietro Lapidari, Youenn Drouet, Emilie Thomas, Jérémie Jacquemin, Maria Alice Franzoi, Martina Pagliuca, Sophie Laurent, Chayma Bousrih, Maryam Lustberg, Olivier Tredan, Anne-laure Martin, Catherine Gaudin, Christelle Jouannaud, Marion Fournier, William Jacot, Marina Rousseau, Jean Francois Deleuze, Alain Viari, Ines Vaz-Luis, Antonio Di Meglio
3. Systemic inflammation, unhealthy behaviors, and cancer-related fatigue (CRF) among survivors of breast cancer (BC)
ESMO Congress 2024 Abstract 1819MO DOI: 10.1016/j.annonc.2024.08.1915
A. Di Meglio, J. Havas, M. Pagliuca, M.A. Franzoi, D. Soldato, B. Pistilli, F. Joly Lobbedez, P.H. Cottu, O. Tredan, A. Bertaut, P. Ganz, J. Bower, A.H. Partridge, A. Martin, S. Everhard, S. Boyault, S. Broutin, S. Michiels, C. Sarre-Pradon, I.V. Vaz Luis
4. Development and validation of a predictive model of aromatase inhibitor musculoskeletal toxicity (AIMT) among patients (pts) with early breast cancer (EBC)
ESMO Congress 2024 Abstract 1818MO DOI: 10.1016/j.annonc.2024.08.1914
P. Lapidari, M. Lustberg, J. Havas, M. Pagliuca, C. Bousrih, C. Jouannaud, M. Fournier, W. Jacot, L. Vanlemmens, C. Kaderbhai, O. Tredan, C. Levy, A. Martin, C. Gaudin, G. Menvielle, M.A. Franzoi, I.V. Vaz Luis, A. Di Meglio
5. Trajectories of cancer-related behavioral symptoms (CRBS) burden after breast cancer (BC).
2024 ASCO Annual Meeting Abstract #: 12038 DOI: 10.1200/JCO.2024.42.16_suppl.12038
Martina Pagliuca, Julie Havas, Pietro Lapidari, Gwenn Menvielle, Leonor Fasse, Diane Boinon, Anne-Laure Martin, Sibille Everhard, Christelle Jouannaud, Marion Fournier, William Jacot, Laurence Vanlemmens, Coureche Kaderbhai, Florence Joly, Michelino De Laurentiis, Florian Scotte, Stefan Michiels, Maria Alice B Franzoi, Ines Maria Vaz Duarte Luis, Antonio Di Meglio
6. Patterns of depressive symptoms among survivors of early-stage breast cancer (BC).
2024 ASCO Annual Meeting Abstract #: 12009 DOI: 10.1200/JCO.2024.42.16_suppl.12009
Antonio Di Meglio, Cécile Charles, Julie Havas, Martina Pagliuca, Pietro Lapidari, Gwenn Menvielle, Leonor Fasse, Diane Boinon, Aurelie Bardet, Alicia Larive, Anne-Laure Martin, Sibille Everhard, Christelle Jouannaud, Marion Fournier, William Jacot, Laurence Vanlemmens, Coureche Kaderbhai, Stefan Michiels, Maria Alice B Franzoi, Ines Vaz-Luis
7. Aromatase inhibitor musculoskeletal toxicity (AIMT) in patients (pts) with early breast cancer (EBC): Prevalence, management, and association with non-adherence to AI.
2024 ASCO Annual Meeting Abstract #: 12122 DOI: 10.1200/JCO.2024.42.16_suppl.12122
Pietro Lapidari, Maryam B. Lustberg, Julie Havas, Martina Pagliuca, Maria Alice B Franzoi, Gwenn Menvielle, Barbara Pistilli, Christelle Jouannaud, Baptiste Sauterey, Olivier Tredan, Paul H. Cottu, Christelle Levy, Florence Lerebours, Sibille Everhard, Anne-Laure Martin, Ines Maria Vaz Duarte Luis, Antonio Di Meglio
8. Comparing the genomic landscape of de novo vs recurrent metastatic breast cancer by ctDNA and tissue profiling
ESMO Breast Cancer 2024 Abstract 52P DOI: 10.1016/j.esmoop.2024.103059
F. Giugliano, J.R. Dixon Douglas, A. Tran Dien, M. Pagliuca, L. Minot, E. Rouleau, A. Bayle, G. Curigliano, B. Verret, A.A. Viansone, M.F. Mosele, B. Pistilli, F. André, A. Italiano, J.T.L. Ribeiro Mourato
9. The influence of ethnicity on cyclin-dependent kinase inhibitors efficacy: A systematic review and meta-analysis
ESMO Breast Cancer 2024 Abdtract 229P DOI: 10.1016/j.esmoop.2024.103251
R. Buonaiuto, A. Caltavituro, M. Pagliuca, M. Tafuro, A. Longobardi, G. Pavone, P. De Santis, L. Del Mastro, F. Puglisi, M. Giuliano, G. Arpino, M. De Laurentiis
10. Germline and acquired genetic variants and long-term cancer-related fatigue among survivors of early-stage breast cancer (BC).
San Antonio Breast Cancer Symposium (SABCS) 2023 Abstract PO4-14-05 https://doi.org/10.1158/1538-7445.SABCS23-PO4-14-05
Antonio Di Meglio Emilie Thomas Youenn Drouet Jean-Baptiste Micol Davide Soldato Maria Alice Franzoi Martina Pagliuca Julie Havas Anne-Laure Martin Sibille Everhard Celine Besse Anne Boland Christophe Marzac Nathalie Droin Sandrine Boyault Marina Rousseau Olivier Trédan Paul Cottu Christelle Jouannaud Marion Fournier Laurence Vanlemmens CHARLES COUTANT Asma Dhaini Merimeche Baptiste Sauterey Florence Joly Mario Campone Florence Lerebours Marie-Ange Mouret-Reynier Olivier Rigal Thierry Petit Sophie Guillermet Antoine Arnaud Mahmoud Ibrahim Sylvie Giacchetti Florence Dalenc Johanna Wassermann Olivier Arsène Ariane Darut-Jouve Aurélie Bertaut Fabrice André Jean-Francois Deleuze Alain Viari Ines Vaz Luis
11. ATTITUDE – ATTrition In longiTUDinal studiEs of cancer survivors (CS): Can we improve the experience of patients (pts)?
ESMO Congress 2023 Abstract 2130P DOI: https://doi.org/10.1016/j.annonc.2023.09.912
C.K. Chiodi, E. Martin, M.A. Franzoi, M. Pagliuca, D. Soldato, P. Lapidari, A. Barbier, J. Havas, J. Arvis, D. Boinon, G. Menvielle, L. Golli, R. Desjardin, G. Jacob, I.V. Vaz Luis, A. Di Meglio
12. Training and validation of a model predicting clusters of long-term cancer-related behavioral symptoms (CRBS) after breast cancer (BC)
2023 ASCO Annual Meeting DOI: 10.1200/JCO.2023.41.16_suppl.12087 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) 12087-12087.
Martina Pagliuca, Julie Havas, Florence Lerebours, Olivier Rigal, Thierry Petit, Sylvie Giacchetti, Florence Dalenc, Johanna Wassermann, Olivier Arsene, Anne-Laure Martin, Sibille Everhard, Ines Maria Vaz Duarte Luis, Antonio Di Meglio
13. Towards improvement of oncology care through digital technology: A snapshot of Resilience remote patient monitoring (RPM) system implementation across 19 hospitals in Europe
2023 ASCO Annual Meeting DOI: 10.1200/JCO.2023.41.16_suppl.1518 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) 1518-1518.
Arlindo R. Ferreira, Antoine Lemaire, Joseph Rodriguez, Jessica Grosjean, Joana M Ribeiro, Laura Polastro, Thomas Grellety, Xavier Artignan, Katell Le Du, Martina Pagliuca, Élodie Nouhaud, Maximilien Autheman, Fabrice Andre, Ethan Basch, Otto Metzger, Mario Di Palma, Florian Scotte, Ines Maria Vaz Duarte Luis Maria Alice B Franzoi
14. Single molecule localization microscopy for nanoscale detection of extracellular vesicles in cancer
EACR 2023 Abstract #: 0885
M.Triki, M. Pagliuca, C. Schietroma, C. Butler, B. Verret, A. Italiano, F. André
15. Trastuzumab plus lapatinib or chemotherapy in patients with HER2-positive advanced breast cancer refractory to anti-HER2 therapies: A randomized, multicenter, phase II trial (GIM12-TYPHER)
ESMO Breast Cancer 2023 Abstract 209P DOI: https://doi.org/10.1016/j.esmoop.2023.101398
C. De Angelis, M. Pagliuca, T. Gamucci, M. Mansutti, Z. Ballatore, M. De Laurentiis, R. Bordonaro, A. Pazzola, V. Leonardi, D. Bruzzese, A.M. Mosconi, C. Molica, S. Cinieri, A. Fabi, L. Del Mastro, F. Puglisi, S. de Placido, M. Giuliano, G. Arpino
16. Prevalence of high tumor mutational burden (TMB) in patients with metastatic breast cancer (mBC) assessed by liquid biopsy (LB)
ESMO Breast Cancer 2023 Abstract 29P DOI: https://doi.org/10.1016/j.esmoop.2023.101253
J.T.M.L.M. Ribeiro, A. Tran Dien, L. Mignot, M. Pagliuca, E. Rassy, M.F. Mosele, T. Grinda, A.A. Viansone, A. Géraud, B. Verret, A. Bayle, B. Pistilli, F. André, A. Italiano
17. Single molecule localization microscopy for extracellular vesicles detection in cancer
ESMO MAP Congress 2022 Abstract 38P DOI: https://doi.org/10.1016/j.annonc.2022.09.039
M. Pagliuca, M. Triki, C. Schietroma, C. Butler, B. Verret, A. Italiano, D. Planchard, A. Bayle, F.André, S. Delaloge
18. Immune checkpoint inhibitors addition to chemotherapy in older patients with metastatic triple negative breast cancer: A systematic review and meta-analysis
ESMO Congress 2022 Abstract 258P DOI: https://doi.org/10.1016/j.annonc.2022.07.297
M. Pagliuca, L. Bencivenga, K. Komici, C. De Angelis, R. Caputo, F. Napolitano, D. Cianniello, V. Di Lauro, G. Rengo, S. De Placido, F. André, M. De Laurentiis
19. CDK4/6 inhibitors in hormone receptor-positive, HER2- negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approaches
ESMO Breast Cancer 2022 Abstract 105P DOI: https://doi.org/10.1016/j.annonc.2022.03.121
S. Parola, V. Di Lauro, P. De Placido, V. Forestieri, G. Buono, C. von Arx, E. Pietroluongo, M. Pagliuca, D. Cianniello, R. Lauria, R. Caputo, G. Arpino, S. de Placido, M. Giuliano, M. De Laurentiis, C. De Angelis
20. Circulating tumor cells count in prostate cancer patients treated with enzalutamide: the LANZA Study.
2019 AIOM National Congress Abstract#: E12 DOI: 10.1177/0300891619872589
Morra R., Zappavigna S., Facchini G., Ribera D., Morelli F., Luce A., Iaccarino S., Izzo M., Scafuri L., Riccio V., Costabile F., Pagliuca M., Abate M., Carrano S., Rossetti S., Giuliano M., De Placido S., Caraglia M., Buonerba C., Di Lorenzo G.
21. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.
2017 ASCO Annual Meeting Abstract #: e16503 DOI: 10.1200/JCO.2017.35.15_suppl.e16503
Carlo Buonerba, Guru Sonpavde, Gregory Russell Pond, Martina Pagliuca , Sabrina Rossetti, Gaetano Facchini, Sarah Scagliarini, Bruno Daniele, Piera Federico, Franco Morelli, Giacomo Cartenì, Matteo Ferro, Giuseppe Lucarelli, Teresa Bellelli, Sabino De Placido, Giuseppe di Lorenzo
Corsi
Dottorato in Clinical and Translational Oncology
News
